Innovative Therapeutics for Better Health
Employees: 11-50
Total raised: $244.8M
Founded date: 2016
Investors 3
| Date | Name | Website |
| - | Lumira Ven... | lumiravent... |
| - | RA Capital... | racap.com |
| - | TPG | tpg.com |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 01.03.2021 | - | $80M | - |
| 17.09.2019 | IPO | $90.8M | - |
| 26.04.2019 | Series B | $62M | - |
| 09.01.2017 | Series A | $12M | RA Capital... |
Mentions in press and media 19
| Date | Title | Description |
| 13.10.2021 | Satsuma Pharmaceuticals : Announces the Appointment of Mutya Harsch to its Board of Directors | South San Francisco, CA, October 12, 2021 - Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candi... |
| 11.05.2021 | SATSUMA PHARMACEUTICALS, INC. Satsuma Pharmaceuticals : Reports First Quarter 2021 Financial Results and Recent Business Highlights | South San Francisco, CA, May 11, 2021 - Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101, a novel therapeutic product candidate for the acute treatment of migraine, today reported fi... |
| 01.03.2021 | Satsuma Pharmaceuticals Announces $80 Million Private Placement Financing | SOUTH SAN FRANCISCO, Calif., March 01, 2021 (GLOBE NEWSWIRE) — Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that it has agreed to sell 14,084,507 shares of its common stock to cert... |
| 01.03.2021 | Satsuma Pharmaceuticals Announces $80 Million Private Placement Financing | SOUTH SAN FRANCISCO, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that it has agreed to sell 14,084,507 shares of its common stock to cer... |
| 10.11.2020 | Satsuma ASCEND trial results expected to support STS101 NDA filing in Q4 2021 | SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) — Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company focused on developing STS101 (a dihydroergotamine (DHE) nasal powder) for the acute treat... |
| 06.08.2020 | Satsuma Pharmaceuticals Announces Enrollment of First Patient in the ASCEND™ Phase 3 open-label, safety trial of STS101 | ASCEND results expected to support STS101 NDA filing in Q4 2021 |
| 11.03.2020 | Satsuma Reports Q4 2019 & FY2019 Financial Results | SOUTH SAN FRANCISCO, Calif. (GLOBE NEWSWIRE) — Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today reported financial results for the quarter and full-year ended December 31, 2019 and summarized r... |
| 05.03.2020 | Satsuma Pharmaceuticals Appoints Rob Janosky as Chief Commercial Officer | South San Francisco, CA – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced the appointment of Rob Janosky to the newly created position of Chief Commercial Officer. As Satsuma’s Chief... |
| 29.01.2020 | Satsuma Pharmaceuticals Publishes Phase 1 Trial Results | SOUTH SAN FRANCISCO, California (GLOBE NEWSWIRE) — Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced that Phase 1 trial results detailing pharmacokinetics (PK), tolerability, and safet... |
| 17.09.2019 | Satsuma Pharmaceuticals Completes $90.8M Initial Public Offering | SOUTH SAN FRANCISCO, Calif. — Satsuma Pharmaceuticals, Inc. (“Satsuma” or the “Company”) (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine... |
Show more